FDA approves Genzyme pediatric leukemia drug

12/30/2004 | Wall Street Journal, The

The FDA approved Genzyme's leukemia drug, Clolar, assigning orphan status to the drug developed for treating patients age 21 and younger who do not respond to chemotherapy. Genzyme expects the drug to be available in January, at an estimated price of $34,000 per dose. One expert said it is likely the drug also will be used off-label in combination with other treatments for adult patients.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX